Overall, the results from this study supported the application of brain organoids as a model for investigating GLUT1-DS and emphasized their potential for evaluating new therapeutic approaches to enhance glucose metabolism and address epilepsy in patients [152]. The gene discussed is SLC2A1; the disease is epilepsy.